Convalescent plasma therapy for coronavirus disease 2019 in ambulatory versus hospitalized patients: Efficacy and risk of thromboembolism

Safety of COVID‐19 convalescent plasma: A definitive systematic review and meta‐analysis of randomized controlled trials

“…No significant differences in the rate of thromboembolic episodes were recorded between cases and controls, both in the overall analysis and in the analysis restricted to FFP controls. These data, which are in accordance with recent findings by Li and colleagues, 56 are not trivial considering the prothrombotic context of COVID-19 57 and early concerns that CCP could trigger coagulation-related adverse effects. 58 Notably, all thromboembolic events occurring during the study periods were reported in this systematic review, not necessarily only those treatment-related, which it was not possible to extract separately.…”